Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 0.56 |
| ▸ | BRD4 | O60885 | 8/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434946 | 0.86 | BRD4 (0.53) | CREBBPBRD4TDP1L3MBTL1MMP12 | |
| SCHEMBL20715625 | 0.81 | CREBBP (0.54) | CREBBPBRD4TDP1L3MBTL1EP300 | |
| SCHEMBL13090985 | 0.80 | BRD4 (0.43) | CREBBPBRD4TDP1L3MBTL1MMP12 | |
| SCHEMBL1038757 | 0.79 | SMN1; SMN2 (0.52) | CREBBPBRD4TDP1L3MBTL1IDO1 | |
| SCHEMBL12062505 | 0.77 | ACHE (0.58) | CREBBPBRD4MMP12EPHX2SIRT1 | |
| SCHEMBL9366324 | 0.77 | CREBBP (0.58) | CREBBPBRD4EP300 | |
| SCHEMBL6219390 | 0.77 | CREBBP (0.58) | CREBBPBRD4EP300 | |
| SCHEMBL434921 | 0.77 | CREBBP (0.58) | CREBBPBRD4EP300 | |
| Hydrochloric Acid SCHEMBL30293268 | 0.75 | CREBBP (0.56) | CREBBPBRD4EP300 | |
| SCHEMBL4909665 | 0.75 | BRD4 (0.65) | CREBBPBRD4MMP12EPHX2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | CREBBP 2543/4885BRD4 1807/4885TDP1 3782/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | CREBBP 2543/4885BRD4 1807/4885TDP1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.